385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa?) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen

G.Curigliano; O.De Cobelli; M.T.Sandri; L.Zorzino; C.Noberasco; T.De Pas; E.Scardino; V.Formica; S.Manzoni; F.de Braud

首页> 外文期刊>European Journal of Cancer Supplements >385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa?) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen

【24h】

385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa?) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen

机译：385一项II期临床试验，评估吉非替尼（Iressa？）在使用黄体激素释放激素类似物（或睾丸切除术后）加抗雄激素治疗的转移性激素难治性前列腺癌（HRPC）患者中的疗效和安全性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第8期|共2页
作者
G.Curigliano; O.De Cobelli; M.T.Sandri; L.Zorzino; C.Noberasco; T.De Pas; E.Scardino; V.Formica; S.Manzoni; F.de Braud;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax?) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC) [J] . R.Amato, M.Karediy, A.Cao, European Journal of Cancer Supplements . 2006,第12期

机译：一项113 POSTER II期临床试验，评估了进行性激素难治性前列腺癌（HRPC）患者（pts）中单独MVA5T4（Trovax？）与MVA5T4加粒细胞巨噬细胞集落刺激因子（GM-CSF）的活性
2. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: The randomised, phase 2 MRC PATCH trial (PR09) [J] . LangleyR.E., CaffertyF.H., AlhassoA.A., The lancet oncology . 2013,第4期

机译：黄体激素释放激素激动剂或经皮雌激素治疗的局部晚期和转移性前列腺癌患者的心血管结局：MRC PATCH 2期随机研究（PR09）
3. 4019 POSTER Phase III, randomized, open-label study of triweekly docetaxel (tT) vs. biweekly docetaxel (bT) as treatment for advanced hormone refractory prostate cancer (HRPC): findings from an interim safety analysis [J] . P.Kellokumpu-Lehtinen, T.Joensuu, P.Hervonen, European Journal of Cancer Supplements . 2007,第4期

机译：4019 POSTER III期三周多西他赛（tT）与双周多西他赛（bT）作为晚期激素难治性前列腺癌（HRPC）治疗的随机开放标签研究：一项临时安全性分析的结果
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Changes in bone mineral density in men with prostate cancer during treatment with luteinizing hormone-releasing hormone (LHRH) agonist monotherapy. [D] . Conde, Francisco Alcasid, II. 2003

机译：黄体激素释放激素（LHRH）激动剂单药治疗期间前列腺癌男性的骨矿物质密度变化。
6. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients [O] . Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, 2017

机译：PALOMA-3：在有激素受体阳性人类表皮生长因子受体2阴性的绝经前和绝经后妇女中使用或不使用帕博西利的氟维西汀的III期试验已在先前的内分泌治疗中进展阴性转移性乳腺癌—亚洲患者的安全性和有效性
7. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients [O] . Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, 2017

机译：paLOma-3：氟维司群有或没有palbociclib的绝经前和绝经后妇女的III期试验激素受体阳性，人类表皮生长因子受体2 - 先前内分泌治疗进展的阴性转移性乳腺癌 - 亚洲患者的安全性和有效性
8. Phase I/II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer [R] . DiPaola, R. S. , Weiss, R. , Shih, W. J. 2006

机译：用于治疗激素难治性前列腺癌的13-顺式维甲酸，α干扰素，泰索帝和雌莫司汀（R.I.T.E.）的I / II期试验

385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa?) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen

著录项

相似文献

相关主题

期刊订阅